Introduction
============

In neurosurgery, brain tumors are one of the most threatening diseases affecting human health. It is estimated that 250,000 primary brain tumors occur per year all over the world, and the five-year survival rate is approximately 30% [@B1]. Currently, surgical resection is the best way to treat most tumors in neurosurgery [@B2]. It is important for surgeons to resect tumors completely to reduce tumor recurrence. On the other hand, the function of the normal brain is important; thus, the intraoperative protection of normal tissues is also essential. Achieving both goals intraoperatively is difficult for surgeons.

In current clinical practice, the intraoperative diagnosis and treatment of tumors mainly depend on the experience of surgeons [@B3]. However, due to the vague boundary between tumors and normal tissues, incomplete resection of tumors usually occurs [@B4]. Auxiliary methods such as intraoperative ultrasound imaging or frozen biopsy analysis are difficult to provide precise pathological information of tissues in a short time. Therefore, new methods and techniques that are able to provide precise intraoperative diagnostic information on tumors are urgently needed.

Optical biopsy methods, such as fluorescence spectroscopy and optical coherence tomography (OCT), are a promising approach for achieving the fast and accurate diagnosis of tissues [@B5]. These methods utilize the interaction between light and the examined tissues to acquire the optical properties of the latter and further determine their biochemical or structural properties. Many types of research have been carried out to validate the efficiency of different optical diagnostic methods [@B6].

For fluorescence spectroscopy, Stummer *et al*. [@B7],[@B8] first conducted a phase III trial to evaluate the resection of malignant gliomas using fluorescence-guided surgery with 5-aminolevulinic acid (5-ALA). The results showed that fluorescence derived from 5-ALA enables more complete resection of tumors. Liao *et al*. [@B9]-[@B11] combined 5-ALA-induced fluorescence with laser ablation to treat brain tumors. The results showed that the system worked well for the precise diagnosis and treatment of brain tumors. Lazarides *et al*. [@B12] also proposed a fluorescence-guided laser ablation system for removing residual cancer. Fluorescence imaging was used as a depth-estimation tool. Schebesch *et al*. [@B13],[@B14] showed that fluorescein sodium (NaFL) was safe and effective for guiding the resection of brain tumors. However, diagnostic methods using extrinsic fluorophores may face problems for low-grade tumors. Another way to distinguish different tissues using intrinsic fluorophores instead of extrinsic fluorophores is autofluorescence spectroscopy. Because tumors and normal tissues have different contents of intrinsic fluorophores, such as proteins, collagen, and lipids, some spectral parameters can be used to judge the properties of tissues. Nguyen *et al*. [@B15] used near-infrared autofluorescence spectroscopy to analyze the margin of soft tissue sarcomas and obtained an accuracy of 88% for tumor classification. Croce *et al*. [@B16] used autofluorescence emission under excitation at 366 nm to discriminate different liver tissues and suggested that autofluorescence-based optical biopsy techniques could be used for the real-time diagnosis of liver diseases. In our previous study, we applied autofluorescence spectroscopy to classify different types of spinal cord tumors [@B17]. The results showed that autofluorescence spectroscopy could be used for the diagnosis of tumors in neurosurgery.

OCT, a label-free, radiation-free and high-speed imaging tool, is an emerging *in vivo* imaging modality widely used in ophthalmology and dermatology [@B18]. By measuring the echoes of backscattered light, OCT shows the internal structural information of biological tissues with cross-sectional and three-dimensional images. Due to its noninvasive, noncontact and high-resolution features, OCT is suitable for intraoperatively discriminating the tumorous areas from the normal areas in neurosurgery [@B19],[@B20]. Jeon *et al*. [@B21] and Lopez *et al*. [@B22] used OCT to differentiate gray matter from white matter to study the feasibility of deep-brain stimulation probe guidance. Böhringer *et al.* [@B23] demonstrated that OCT could discriminate normal brain, areas of tumor-infiltrated brain, solid tumor, and necrosis. Bizheva *et al*. [@B24] imaged the brain morphology of animal models with ultrahigh-resolution OCT. Boppart *et al*. [@B25] constructed a pen-sized handheld surgical imaging probe and evaluated the feasibility of using OCT as a real-time intraoperative imaging technique to identify an intracortical melanoma. Kut *et al*. [@B26] used OCT to detect and quantitatively differentiate cancerous tissues from noncancerous tissues in human brain models. To discriminate tumors and identify the tumor margin, methods with cross-sectional characteristics [@B27],[@B28], *en face* characteristics [@B29] and cross-referencing optical characteristics were proposed [@B30]. Research has demonstrated that intraoperative brain tumor diagnosis using OCT is effective.

However, single-modality optical methods do not easily satisfy the precise diagnostic requirements of tumors in neurosurgery. Thus, methods and systems based on multimodality optical information have been proposed [@B31]. Kantelhardt *et al.* [@B32] first applied multiphoton and fluorescence lifetime imaging for *in vivo* imaging during neurosurgical procedures. Jermyn *et al*. [@B33] combined intrinsic fluorescence spectroscopy, diffuse reflectance spectroscopy and Raman spectroscopy for intraoperative cancer detection, and the experimental results showed high diagnostic accuracy. Mohs *et al*. [@B34] developed a handheld spectroscopic device based on fluorescence and surface-enhanced Raman scattering for *in vivo* tumor detection. However, the imaging view of their methods was limited. Barton *et al*. [@B35] and Hariri *et al*. [@B36] applied endoscopic OCT-LIF (OCT-laser-induced fluorescence spectroscopy) to a murine colon cancer model and successfully identified the cancerous regions from the normal tissues. Jung *et al*. [@B37] and Ryu *et al*. [@B38] proposed a dual-channel fiber scanning probe to obtain the swept source OCT (SS-OCT) images and the fluorescence spectrum simultaneously. Barton *et al*. [@B39] compared the B-scan OCT images with a line of light spots of fluorescence spectrum along the OCT scanning line. However, the two kinds of information were not combined to provide diagnostic results. Fan *et al*. [@B40] used bioluminescence imaging and two-photon microscopy to guide the laser ablation of brain tumors. The experimental results suggest that the proposed method could extend the lifetime of mice used for the model, but there is a lack of structural depth information.

OCT provides information on the micrometer-level microstructure of biological tissues based on optical characteristics, while quantitative autofluorescence spectroscopy reveals the differences in the biochemical composition of the tissue. By combining these two modalities, better functional and structural diagnosis can possibly be obtained than either modality alone. Therefore, in this study, we developed a precise point-to-face registration-based dual-modality optical diagnostic method for brain tumors and normal tissues in neurosurgery. An *in vivo* quantitative autofluorescence spectroscopy measurement module and an OCT module were established. We established a batch of mouse models with brain tumors and used bioluminescence imaging to provide preoperative information. The quantitative autofluorescence spectroscopy and OCT imaging were performed, and their information was combined to provide a precise diagnostic map. Pathological information was used to evaluate the effectiveness of our proposed method. Our main contributions include three aspects:

1\) Previous studies have only combined several points of fluorescence information with OCT to provide diagnostic results, which were difficult for surgeons to judge the tumor margin and stage precisely. In this study, we proposed a point-to-face registration-based dual-modality optical diagnostic method, which could provide a precise 2-D diagnostic map containing both biochemical and structural information of tissues for surgeons. Thus, the information provided by our method is more comprehensive and accurate.

2\) Compared with current techniques that were used in neurosurgery such as the frozen-biopsy method and fluorescence imaging, our method was able to provide more quantitative and robust diagnostic results in a short time.

3\) The proposed method is universal and easy to use in similar optical diagnostic systems. We believe that our work will be of great worth for intraoperative guidance and future intelligent theranostic system in neurosurgery.

Methods
=======

Optical diagnosis system flowchart
----------------------------------

The flowchart of our study is shown in **Figure [1](#F1){ref-type="fig"}**. We built a murine model by injecting U87MG human glioma cells into the brain of a mouse. Before surgery, bioluminescence imaging was used to evaluate the growth state of the tumor and to locate the tumor sites. During surgery, *in vivo* quantitative autofluorescence spectroscopy and OCT information was acquired and combined to help surgeons judge the properties of the tissues. Quantitative autofluorescence spectroscopy mainly provided precise local biochemical information, while OCT mainly provided global structural information of tissues. The postoperative pathology was used to evaluate the fast optical diagnosis.

Animal model establishment
--------------------------

In total, 16 female BALB/c-Nu nude mice at 6-8 weeks of age were used to establish the brain tumor model. The laboratory animal facility was accredited by AAALAC (Association for Assessment and Accreditation of Laboratory Animal Care International), and the IACUC (Institutional Animal Care and Use Committee) of Tsinghua University approved all animal protocols (No. 17-LHE1 and No. 18-LHE1) used in this study.

A human U87MG glioma cell line labeled with the luciferase gene was acquired. Before cell injection, the weight of each nude mouse was recorded. Anesthesia was performed using 0.4% pentobarbital sodium at a dose of 16 μL/g. After anesthesia, the mouse was placed on a stereotaxic frame. An incision with a diameter of 5 mm was made, and craniotomy was performed. A 7 μL cell suspension containing approximately 5×10^5^ cells was injected into the cortex of the parietal lobe approximately 1 mm below the skin. Then, the opening in the skull was closed using bone wax, and the wound was sutured. After injection, the nude mice were maintained under sterile conditions for two weeks.

We also established another C6 rat model for the evaluation of our method. In total, eight male SD rats at 6-8 weeks of age were used. Anesthesia was performed using 3% pentobarbital sodium at a dose of 10 μL/g, and a 10 μL cell suspension containing approximately 5×10^5^ C6 cells was injected into the cortex of the parietal lobe. After injection, the rats were maintained under sterile conditions for eight days.

Bioluminescence imaging module
------------------------------

Bioluminescence imaging was used to evaluate the growth states of tumors and provide preoperative information before surgery. Before bioluminescence imaging, the weight of each mouse was recorded. Then, a 15 mg/mL D-luciferin potassium salt solution in D-PBS (Dulbecco\'s phosphate-buffered saline, without Mg^2+^ and Ca^2+^) was intraperitoneally injected into the mouse at a dose of 10 μL/g ten minutes before imaging. Afterwards, bioluminescence imaging was performed to locate the tumor sites and guide the surgeons in making the treatment plan.

*In vivo* quantitative autofluorescence spectroscopy module
-----------------------------------------------------------

The quantitative autofluorescence spectroscopy module mainly consisted of a 150-W xenon light source, an excitation monochromator (Omni-3028i; Zolix Instrument, Beijing, China), a 6-around-1 Y-type fiber-optic probe (QR400-7-SR; Ocean Optics, Florida, USA), an X-Y motorized precision translation stage (GCD-202050M; Daheng Optics, Beijing, China), an emission monochromator, an electron-multiplying charge-coupled device (EMCCD) camera (iXon Ultra 888; Andor Technology, Oxford, UK) and a data acquisition device, as shown in **Figure [2](#F2){ref-type="fig"}**.

To provide precise information about the stage and boundary of the tumor, some preliminary *ex vivo* experiments were necessary. We set the excitation wavelength to vary from 300 nm to 450 nm at 10-nm increments and acquired the excitation-emission matrixes (EEM) of the tumorous and normal tissues. Then, we were able to obtain the optimal excitation bands by calculating the peak intensity ratios and analyzing the difference between tumorous and normal tissues. *In vivo* measurements and diagnoses were performed using these excitation wavelengths. Dark noise was recorded for data analysis, and the spectrum at 300-nm excitation was measured again at the end of each measurement to determine if photobleaching occurred.

SS-OCT module
-------------

We used SS-OCT to image the brain tissues. The SS-OCT module consisted of a MEMS-based swept source (HSL-20-100-B, Santec Technologies, central wavelength: 1310 nm; power: 20 mW; bandwidth: 80 nm), a balanced photodetector (Thorlabs, INT-MSI-1300B), a data acquisition device (ATS9350, Alarztec Technologies, sampling rate: 500 M/s) and other components. The OCT equipment could provide images with 12 μm axial resolution and 22 μm lateral resolution. The depth of field of the OCT scanning objective lens was ![](thnov09p2827i001.jpg)0.8 mm. A schematic of the SS-OCT module is shown in **Figure [3](#F3){ref-type="fig"}**.

A series of image preprocessing procedures were conducted to prepare the original images for *en face* map acquisition (**Figure [4](#F4){ref-type="fig"}(A)**). First, to distinguish the tissue parts from the aerial parts in each OCT image, we set a proximate threshold to find the tissue upper surface locations and saved them in a 2-D matrix. Second, to remove the fixed-pattern noises and correct the locations, we compared the value of each location with the values of its four neighboring locations to identify the abnormal mutations. Third, based on the upper surface locations, we saved the data of tissue parts along the upper surface with one chosen thickness (every A-scan had the same pixels). This way, the prepared OCT data showed roughly the same physical depth as that of tissues. During the imaging process, we tried to set the position of the brain to make the imaging plane horizontal in order to weaken the intensity change caused by the difference in imaging distance.

We used a simplified exponential function [@B26] to express the signal intensity along the depth:

(2-1)

where ![](thnov09p2827i003.jpg) is the tissue pixel depth from the surface, *A* is the overall coefficient, ![](thnov09p2827i004.jpg)is the backscattering coefficient, ![](thnov09p2827i005.jpg) is the total attenuation coefficient, multiplier 2 is the round-trip travel of light in the tissue, and ![](thnov09p2827i006.jpg) is the point spread function. Based on the function (2-1), we obtained the *en face* map (**Figure [4](#F4){ref-type="fig"}(B)**) of the total attenuation coefficient extracted from each A-scan using the FD (frequency-domain) method [@B29]. In this method, the ratio of the discrete Fourier transform of normalized signal intensities on any two harmonics was used to calculate the total attenuation coefficient. The intensity was normalized by a phantom, and the discriminating capability of this method was insensitive to the phantom coefficient. The attenuation coefficient of each A-scan data point along the imaging depth was calculated separately.

Point-to-face registration-based dual-modality information fusion and evaluation
--------------------------------------------------------------------------------

The autofluorescence spectral map that provided local biochemical information was matched with the OCT *en face* map that provided global structural information, as shown in **Figure [5](#F5){ref-type="fig"}**. After craniotomy, the tumorous area was exposed. We used India ink to label several points to ensure that the scanning area for quantitative autofluorescence spectroscopy and OCT was consistent. Then, spectral data scanning and OCT imaging were performed. The spectral data of the area were acquired and processed including dark noise subtraction and normalization. Some featured spectral parameters were extracted, and binary classification was performed to generate a spectral map of the tissue surface. The OCT images were also processed as described above, and an *en face* map was generated. The spectral information was mapped to the global OCT information after data scanning.

During the information fusion process, the final diagnostic map was acquired by calculating the union set of the spectral map and the *en face* map. The intersection of the two maps was considered the central part of the tumorous tissues, and the other parts were considered tumors either by quantitative autofluorescence spectroscopy alone or by OCT alone.

To evaluate the actual area of the tumor, we calculated the tumorous area in pathology by an approximation method (**Figure [6](#F6){ref-type="fig"}**). The whole brain was frozen, and the imaging target region was cut along the mark of India ink to minimize the deformation. Then, the tissue was embedded in a wax block, yielding dozens of cross-sectional pathological sections that were almost uniformly distributed. We regarded the rectangular region around the section as having the same pathological features as the section and got the approximate pathological map. The tumorous area on the OCT *en face* map, the diagnostic lattice of autofluorescence spectroscopy and the fused map were outlined by the surgeon and compared with the pathological map to calculate the sensitivity (the proportion of the actual tumorous part that was correctly identified) and specificity (the proportion of the actual normal part that was correctly identified).

Results
=======

The whole optical measurement system, including the autofluorescence spectral scanning module and the OCT module, is shown in **Figure [7](#F7){ref-type="fig"}**.

We first established the tumor mouse model and maintained these 16 mice for two weeks in the experimental animal center of Tsinghua University. We divided these mice into two groups: the first group contained eight mice for *ex vivo* quantitative autofluorescence spectroscopy and OCT imaging to acquire the optimal detecting parameter; the second group contained eight mice for *in vivo* measurement and information fusion to evaluate the proposed method. Before surgery, all mice were examined in the bioluminescence imaging system (IVIS Spectrum, PerkinElmer, USA) to locate the tumor and evaluate its size (**Figure [8](#F8){ref-type="fig"}**). After bioluminescence imaging, craniotomy was performed by the neurosurgeon, and the tumorous areas were exposed for subsequent measurements. The bioluminescence lasted for 2-3 h after the injection of luciferin. We acquired the optical information three hours after the bioluminescence imaging to avoid the influence of the bioluminescence.

Quantitative autofluorescence spectroscopy measurement
------------------------------------------------------

We set up the quantitative autofluorescence spectroscopy module as shown in **Figure [7](#F7){ref-type="fig"}**. To acquire the optimal spectral parameters for differentiating tumorous tissues from normal tissues, we conducted *ex vivo* measurement experiments. We obtained some normal and tumorous tissues, and the properties of these tissues were validated by pathological diagnosis.

During the measurement process, the integration time of the EMCCD camera was set to 0.5 s, the EM (electron-multiplying) gain was set to 10 times, and the cryogenic temperature was set to -60°C. The EEMs of the normal and tumorous tissues are shown in **Figure [9](#F9){ref-type="fig"}(A)-(B)**. From the EEMs, we saw that the two types of tissues had different spectral properties. To quantitatively distinguish tumors from normal tissues, we extracted some featured emission peaks and calculated the peak intensity ratios. The emission spectra at excitation wavelengths of 380 nm and 450 nm are shown in **Figure [9](#F9){ref-type="fig"}(C)-(D)**.

We then extracted the intensity ratios, R~1~: I~380-462~/ I~380-614~ (I~380-462~ indicates the intensity at the emission wavelength of 462 nm when excited by 380 nm) and R~2~: I~450-550~/I~450-612~. The distributions of the two ratios are shown in **Figure [9](#F9){ref-type="fig"}(E)-(F)**. Tumorous tissues showed low R~1~ and R~2~ values (\<1), while normal tissues showed high R~1~ and R~2~ values (\>1). These two ratios were used as the featured parameters for subsequent tumor boundary division. The main reason for the different spectral properties of tumorous and brain tissues might be the different contents of intrinsic fluorophores [@B41], such as collagen or flavins. Different studies have reported different optimal bands and parameters for brain tumor identification [@B42],[@B43], possibly because the tumor type and the measurement mode were different.

To determine the relationship between quantitative autofluorescence spectroscopy and tumor stage, we performed the spectral measurement using two mice in the first group at each time every three days after the tumor cell injection. We acquired the spectral information of the tumors at excitation wavelengths of 380 nm and 450 nm. For each mouse, at least three tumorous points were measured for spectral analysis. Then, we extracted the peak intensity ratios from each data and averaged them for further analysis. The results are shown in **Figure [10](#F10){ref-type="fig"}**. As the tumor stage increased, the featured parameters R~1~ and R~2~ trended downward.

OCT image processing
--------------------

By imaging the tumor in a 5 mm ![](thnov09p2827i007.jpg) 5 mm square region, we obtained an image cube with a size of 250 (A-scan) ![](thnov09p2827i008.jpg) 500 (B-scan) ![](thnov09p2827i009.jpg) 200 (C-scan) pixels. The imaging depth was approximately 2 mm, as measured by the pixels of the longitudinal sectional photograph of the tissues. To further remove the fixed-pattern noises around the corner and confirm that all the A-scan data have enough depth to be flattened, we manually cropped the image into a 250 ![](thnov09p2827i010.jpg)341 ![](thnov09p2827i011.jpg)180 cube with all the tumorous regions. In the 3-D OCT cube rendered by triangle patches, the tumor resembled a hump that was conspicuously higher than the normal surrounding tissues, corresponding to the tumorous region visible by the naked eye. The greatest height of the tumor out of the normal tissue was approximately 0.8 mm. The height difference caused by the natural unevenness of the whole brain reached 1.5 mm. During the imaging process, we found that the attenuation coefficient difference had already appeared when the tumor height was very small. That means in our experiment, the difference in the attenuation coefficient had little relationship with its height, and the intensity change caused by the height of tumor was acceptable within the whole image.

### Preprocessing of the OCT image

A cross-sectional OCT image is shown in**Figure [11](#F11){ref-type="fig"}(B)**. By exponentially fitting the A-scan intensity curves in the tumorous region (blue curve in **Figure [11](#F11){ref-type="fig"}(A)**) and the normal region (red curve in **Figure [11](#F11){ref-type="fig"}(A)**), a notable difference in the attenuation coefficient can be observed**(Figure [11](#F11){ref-type="fig"}(C)**). After we removed the fixed-pattern noises marked by white arrows in **Figure [11](#F11){ref-type="fig"}(D)**, we obtained the upper surface of the tissue in the B-scan image. Due to the characteristics of the OCT image, the darker area in **Figure [11](#F11){ref-type="fig"}(D)** marked by the yellow arrow was likely to reveal weak light incidence (which was caused by the strong backscattering or back-reflecting tissues above) rather than weak backscattering. Thus, we cropped the most reliable data at a depth of 50 pixels from the surface (region outlined by the red dashes in **Figure [11](#F11){ref-type="fig"}(D)**) and flattened them (**Figure [11](#F11){ref-type="fig"}(E)**).

### En face map and threshold selection

The *en face* map, which consisted of the total attenuation coefficients of all the A-scan data, is shown in **Figure [12](#F12){ref-type="fig"}(B)**. The tumorous region outlined by the red dashes showed a higher attenuation coefficient, possibly due to the increased density of the cell nuclei (refer to **Figure [12](#F12){ref-type="fig"}(D)**). The pathology (**Figure [12](#F12){ref-type="fig"}(D)**) at the same OCT B-scan line showed good agreement with the OCT image (**Figure [12](#F12){ref-type="fig"}(C)**).

To improve the diagnostic results of the OCT *en face* map, we cropped the target area (the blue square region in **Figure [13](#F13){ref-type="fig"}(A)**) around the tumor. The binary map of the target area was calculated separately with nine thresholds and is shown in **Figure [13](#F13){ref-type="fig"}(B)**. To choose the best threshold, the diagnostic decisions made by the surgeon were analyzed by pathology, and the results are shown as the sensitivity (blue)/specificity (red) curves and ROC (receiver operating characteristic) curve in **Figure [13](#F13){ref-type="fig"}(C)** and **Figure [13](#F13){ref-type="fig"}(D)**, respectively. The largest area of the rectangle under the ROC curve appeared at the point where the threshold equaled 6.6. Thus, we chose a threshold of 6.6 with 86.0% sensitivity and the corresponding binary map as the final diagnostic basis. The attenuation coefficient data based on the optimal threshold of 6.6 were calculated and are shown in **Table [1](#T1){ref-type="table"}**.

Optical information fusion and evaluation
-----------------------------------------

We acquired the autofluorescence spectral information and OCT information in a 5 mm ![](thnov09p2827i012.jpg) 5 mm square region with tumorous tissues. For quantitative autofluorescence spectroscopy, we acquired the autofluorescence spectral data in the remaining eight mice. The integration time of the EMCCD camera was set to 0.2 s. The diameter of the light spot of the probe was approximately 1 mm. The monochromatic light source produced an irradiance of 25 mW/cm^2^ on the tissue. The step length of the translation stage was set to 0.5 mm, and the spectral data of 81 points were acquired. During spectral data scanning, emission spectra were recorded from 450 nm to 650 nm at 380 nm excitation and from 500 nm to 650 nm at 450 nm excitation. Then, the R~1~ and R~2~ values of each point were calculated and used for information fusion. We considered the regions to be tumorous tissues where the R~1~ or R~2~ value was smaller than 1.0. For OCT, we binarized the *en face* map with the chosen threshold. The single-modality maps and their fused diagnostic map are shown in **Figure [14](#F14){ref-type="fig"}**.

By comparing the pathology and the diagnostic decision made by the surgeon, we evaluated the sensitivity and specificity of the OCT *en face* maps, the autofluorescence spectral maps, and the fused maps of eight mice, as shown in **Table [2](#T2){ref-type="table"}**.

Detection based on the R~2~ value performed better than detection based on the R~1~ value; thus, we evaluated the fusion map composed of the R~2~ values and the OCT map. The fused map showed a higher sensitivity and lower specificity than did the OCT *en face* map or the quantitative autofluorescence spectral map alone. The average diagnostic sensitivity and specificity of the fused map were 95.9% and 88.7%, respectively.

Discussion
==========

Brain tumors are challenging for neurosurgeons, and one possible reason may be the lack of intraoperative diagnostic information. Currently, different kinds of optical methods have the potential to provide intraoperative information, but they have their own disadvantages. Thus, we have proposed a point-to-face registration-based dual-modality optical method for the diagnosis of tumors in neurosurgery. We combined autofluorescence biochemical information with global OCT structural information to locate the tumor and identify its boundary. We established an animal model and conducted *in vivo* measurement experiments to evaluate the performance of our method. The fusion of the quantitative autofluorescence spectral map and the OCT *en face* map provides an accurate and comprehensive diagnosis of tumors, as our results have shown.

The sensitivity of the fusion map is improved compared to that of the OCT *en face* map or the autofluorescence map alone, while the specificity shows an obvious decline. This phenomenon is possibly due to the low resolution of quantitative autofluorescence spectroscopy compared to that of OCT; thus, normal areas near the tumor boundary are considered tumors by quantitative autofluorescence spectroscopy, leading to the decline in the final specificity. Although properly extending the resection areas is helpful in the treatment of some brain tumors, the resolution of the autofluorescence spectroscopy system (1 mm) still needs improvement. Therefore, in the future, we will improve the resolution of the autofluorescence spectroscopy system by developing new probes and scanning modes.

To evaluate whether our proposed method could be used in other tumor models and compare our method with the fluorescence imaging that has been studied for a long time in neurosurgery [@B44], we built another C6 rat model and used NaFL for fluorescence imaging. We chose NaFL for fluorescence imaging mainly because NaFL has been widely used in clinical surgery [@B14],[@B45]. The drug was administered by intravenous injection, which was more feasible in the animal model. We acquired the optical information four and eight days after tumor cell injection. For fluorescence imaging, we injected the NaFL solution into the tail vein around one hour before the craniotomy at the dose of 10 mg/kg. After craniotomy, we performed fluorescence imaging using a stereoscopic fluorescence microscope (MZ10F, Leica, Germany). We then acquired the dual-modality optical information after fluorescence imaging. Pathology was finally performed to evaluate and contrast the two methods. The results using the two diagnostic methods are shown in **Figure [15](#F15){ref-type="fig"}**. It can be seen that the fluorescence imaging four days after tumor cell injection could not easily identify the tumorous area, while the fluorescence imaging eight days after tumor cell injection was clearer.

The quantitative evaluation of the two methods is given in **Table [3](#T3){ref-type="table"}**. It can be seen that the sensitivity of the fluorescence imaging four days after tumor cell injection was much lower than that of our proposed method, while the sensitivity eight days after tumor cell injection was almost equal to that of our method. The specificity of the fluorescence imaging four days after tumor cell injection was higher than that of our method, while the specificity eight days after tumor cell injection was much lower than that of our method.

The speed of image processing is also an important factor. Fluorescence imaging needs approximately two seconds to yield an image under the proper excitation wavelength. Our proposed method needs three steps to acquire the final fused map. For quantitative autofluorescence spectroscopy, the acquisition of the peak intensity ratio of one point needs approximately 0.5 s, and the time to scan the whole area (81 points) is approximately 40 s. For OCT, the acquisition time of 200 OCT images (250 ![](thnov09p2827i013.jpg) 500 pixels) is approximately four seconds, and the time of image processing to get an *en face* map is approximately 15 s. For information fusion, the time is within 1 s. Thus, the whole processing time of our method is approximately 60 s.

From the experimental results, we can see that the fluorescence imaging for early-stage brain tumors is unsatisfying. Moreover, the fluorescence imaging for late-stage brain tumors may give some false-positive results, leading to a decreased specificity. The diagnostic results of our proposed method are better for early-stage tumors and late-stage tumors. Our method is faster than the current frozen-biopsy method. Compared with single-modality optical methods such as fluorescence imaging, our method is able to provide more accurate and comprehensive information. Both OCT and autofluorescence spectroscopy are able to realize real-time detection. Thus, in the future, we will improve the data acquisition and analysis speed and incorporate the imaging modules to realize real-time intraoperative diagnosis and reduce the impact of manual data registration.

Some researchers have proposed a dual-modality system that is able to obtain fluorescence spectral information and OCT images simultaneously. Ryu *et al*. [@B38] proposed a double-clad combined system, and Barton *et al*. [@B39] proposed a combined instrument based on the beam splitter. However, both groups only combined a cross-sectional OCT image with one or several points of fluorescence along the OCT B-scan line. In such a way, the combined information was limited and inconvenient for the surgeon to locate the tumor or to identify the tumor margin. Pahlevaninezhad *et al*. [@B46],[@B47] proposed a combined autofluorescence and OCT imaging system for fast *in vivo* imaging of tissues. However, the autofluorescence imaging module only contained one excitation band; thus, the autofluorescence information was limited and nonquantitative. The fused map we proposed combined an OCT *en face* map that contained the whole information of a 3-D OCT cube and an autofluorescence spectral lattice that contained dense and overlapped points covering the whole OCT imaging region. In addition, the diagnostic results contained a substantial amount of quantitative information. Thus, we could provide relatively global information and could have the capability to give the surgeon a clear location of the tumor and its margin.

To explain the significance of information fusion, the basic mechanism of autofluorescence spectroscopy and OCT should be considered. The contrast of quantitative autofluorescence spectral information is based on the difference in the biochemical compositions of normal and tumorous tissues. The contrast of OCT images is based on the difference in the optical characteristics of tissues. For example, for the tumorous area, backscattering coefficient and attenuation coefficient may be high, which is mainly caused by an increase in cell density, especially the number of nuclei. Therefore, in our research, the information of the two modalities is complementary:

1\) Margin identification by the OCT *en face* map may face problems when the tumorous regions are infiltrative and transitional. The biochemical composition of this kind of area has changed, and the tissue structure may be unclear. Quantitative autofluorescence spectroscopy is capable of discriminating minor and complex biochemical changes with high sensitivity.

2\) The lateral resolution of quantitative autofluorescence spectroscopy depends on the diameter of the light spots and the step length between the spots. This type of resolution is limited by the instrument and can reach millimeter-level, much lower than the micrometer-level resolution of OCT. Therefore, if the tumorous area is small and the light intensity is low, quantitative autofluorescence spectroscopy may misdiagnose the area as normal tissues. In contrast, OCT is capable of discriminating slight structural changes with high resolution and provides precise margin information.

Therefore, by combining two modalities with the point-to-face registration method, we can acquire intraoperative structural and functional information and provide a large imaging view with an appropriate resolution. Considering the high diagnostic accuracy and speed of our proposed method, incorporating automatic therapeutic methods such as laser ablation to realize an intelligent theranostic system will be possible in the future, which will be helpful for neurosurgeons.

Conclusion
==========

In this paper, we have developed a precise point-to-face registration-based optical diagnostic method for fast tumor identification using the dual-modality optical information of quantitative autofluorescence spectroscopy and OCT. *In vivo* animal experiments validate that the method and system provide a credible tumor location and identify its margin with high sensitivity and specificity compared with pathology. The proposed method is an effective auxiliary tool for the fast and accurate diagnosis of tumors in neurosurgery.
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![The research flowchart of the proposed point-to-face registration-based dual-modality optical diagnostic method for precise identification of tumors in neurosurgery.](thnov09p2827g001){#F1}

![The configuration of the *in vivo* quantitative autofluorescence spectroscopy module.](thnov09p2827g002){#F2}

![Schematic of the SS-OCT module. A 2-D galvo scanner was used. BPD: balanced photodetector.](thnov09p2827g003){#F3}

![**(A)** The preprocessing procedure. **(B)** The *en face* map of an OCT image cube; the tumor position is shown in the 2-D mode.](thnov09p2827g004){#F4}

![The framework of quantitative autofluorescence spectroscopy and OCT information fusion based on the point-to-face registration fusion method.](thnov09p2827g005){#F5}

![**(A)** The diagram of cutting pathological sections.**(B)** The cross-sectional pathological section and its corresponding rectangle.**(C)** The pathological map.](thnov09p2827g006){#F6}

![The dual-modality optical diagnostic system containing the quantitative autofluorescence spectroscopy module and the OCT module.](thnov09p2827g007){#F7}

![Bioluminescence imaging after two weeks of tumor cell injection.](thnov09p2827g008){#F8}

![**(A)** EEM of the brain tissue. **(B)** EEM of the tumorous tissue.**(C)** Spectral curves at 380 nm excitation. The emitted photon numbers of normal tissues and tumorous tissues at the emission wavelength of 462 nm were approximately 4000 and 2000, respectively; the emitted photon numbers of normal tissues and tumorous tissues at the emission wavelength of 614 nm were approximately 2000 and 4000, respectively. **(D)** Spectral curves at 450 nm excitation. The emitted photon numbers of normal tissues and tumorous tissues at the emission wavelength of 550 nm were approximately 1500 and 800, respectively; the emitted photon numbers of normal tissues and tumorous tissues at the emission wavelength of 612 nm were approximately 1000 and 2000, respectively. **(E)** Distribution of R~1~. **(F)** Distribution of R~2~.](thnov09p2827g009){#F9}

![The relationship between the tumor stage and quantitative autofluorescence spectroscopy. **(A-D)** The average spectral curves and the corresponding pathology three, six, nine and 12 days after tumor cell injection. **(E, F)** The trends of the average spectral parameters R~1~ and R~2~ with increasing tumor stage.](thnov09p2827g010){#F10}

![**(A)** The intensity curves of the A-scan data. **(B)** A cross-sectional OCT image. **(C)** The intensity curves for the tissue surface and their exponential fitting curves. The blue curves in (A) and (C) correspond to the blue line in (B), and the red curves in (A) and (C) correspond to the red line in (B). The attenuation coefficients of the red curve and blue curve were 0.0012 and 0.0023, respectively. **(D)** One B-scan OCT image of the cube. **(E)** Flattened OCT data with a thickness of 50 pixels. The fixed-pattern noises are marked by white arrows.](thnov09p2827g011){#F11}

![The *en face* map of attenuation coefficients and other reference information. **(A)** Tissue upper surface. **(B)** The *en face* map of the OCT image cube. **(C)** The OCT image corresponding to the yellow line in (A). **(D)** Pathology corresponding to the image in (C). The tumorous regions are marked by arrows. The tumor margins on the tissue surface were visible to the naked eye and were marked by the surgeon using India ink, as shown by the red dashes in (A) and (B), and short green lines in (C) and (D).](thnov09p2827g012){#F12}

![Binary map processing based on different thresholds.**(A)** The target area in the *en face* map. **(B)** Binary maps under different thresholds. **(C)** Diagnostic sensitivity (blue)/specificity (red) data. **(D)** The ROC curve. The binarization was conducted on the region in the inset outlined by blue lines in (A). The largest area of the rectangle under the ROC curve appeared at the point where the threshold equaled 6.6.](thnov09p2827g013){#F13}

![The fused map of OCT attenuation information and autofluorescence spectral indexes. **(A).** *In vivo* autofluorescence spectral scanning. **(B).** The naked-eye view of the mouse brain. The target scanning area is marked by the red box. **(C).** *In vivo* OCT imaging. **(D).** The spectral maps of R~1~ and R~2~ values of the target areas. **(E).** The OCT *en face* map of attenuation. The area outlined by the blue box was further cropped and binarized as the final map. **(F).** The fused map of the OCT *en face* map and the spectral maps, overlapped by the real scanning area. The tumorous area identified by OCT is in yellow, the tumorous area identified by autofluorescence is in red, the intersection tumorous area of the two modalities is in orange and is outlined by the blue dashes, and the union area is indicated by the black outline.](thnov09p2827g014){#F14}

![The comparison between fluorescence imaging and our proposed method in the C6 rat model four and eight days after tumor cell injection. **(A, B)** The diagnostic results by fluorescence imaging. The tumorous regions are marked by the green dashes. **(C, D)** The fused maps overlapped by the white-light image. The tumorous regions are marked by the orange dashes.](thnov09p2827g015){#F15}

###### 

The attenuation coefficient data of the normal and tumorous tissues when threshold = 6.6 and sensitivity = 86%. The diagnostic data are provided by n = 8 nude mice with brain tumors.

  Tissue         n   Mean (mm^-1^)   SD (mm^-1^)
  -------------- --- --------------- -------------
  **Tumorous**   8   6.982           0.0759
  **Normal**     8   6.285           0.0919

###### 

Evaluation of the OCT, quantitative autofluorescence spectroscopy and fused maps. S.D.: standard deviation.

  Mouse No.   OCT *en face* Map   Autofluorescence R~1~   Autofluorescence R~1~   R~2~ & OCT Fused Map                           
  ----------- ------------------- ----------------------- ----------------------- ---------------------- ------- ------- ------- -------
  1           77.3%               87.1%                   78.6%                   90.6%                  89.3%   94.3%   96.6%   83.4%
  2           87.6%               95.7%                   88.0%                   92.9%                  92.0%   91.1%   96.3%   87.9%
  3           91.2%               98.3%                   86.2%                   88.5%                  96.6%   92.3%   98.5%   85.7%
  4           85.1%               99.1%                   76.7%                   94.1%                  90.0%   94.1%   95.7%   91.5%
  5           86.0%               97.2%                   91.7%                   91.2%                  91.7%   89.5%   95.5%   85.6%
  6           88.3%               93.3%                   86.4%                   93.2%                  95.5%   91.5%   98.1%   90.8%
  7           86.1%               99.0%                   78.6%                   96.2%                  85.7%   96.2%   89.0%   94.3%
  8           86.8%               98.6%                   88.9%                   88.9%                  92.6%   96.3%   97.2%   90.7%
  **Mean**    86.1%               96.0%                   84.4%                   92.0%                  91.7%   93.2%   95.9%   88.7%
  **S.D.**    0.037               0.039                   0.052                   0.025                  0.032   0.023   0.028   0.034

###### 

Evaluation of fluorescence imaging and the proposed dual-modality diagnostic method.

  Method                        Speed (s)   Sensitivity   Specificity                   
  ----------------------------- ----------- ------------- ------------- ------- ------- --
  **Fluorescence imaging**      2           83.5%         97.1%         96.2%   81.2%   
  **Dual-modality fused map**   60          94.1%         96.6%         90.5%   92.4%   
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